
Reports Q3 revenue $2.83M, consensus $5.54M. “This past quarter we continued to advance our Phase 2 B-SUPREME study of pevifoscorvir sodium, which remains on track for the topline data readout
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ALGS | Aligos Therapeutics | 1.25 | -6.69 | -84.26% |
| Name | Price | % Change | |
|---|---|---|---|
| $1.25 | -84.26% |

Reports Q3 revenue $2.83M, consensus $5.54M. “This past quarter we continued to advance our Phase 2 B-SUPREME study of pevifoscorvir sodium, which remains on track for the topline data readout

Aligos Therapeutics ( ($ALGS) ) has issued an update. On September 10, 2026, Aligos Therapeutics, Inc. amended its headquarters lease with Britannia Biotech Gateway Limited Partnership, extending the term for

Aligos Therapeutics, Inc. ($ALGS) announced an update on their ongoing clinical study. Aligos Therapeutics, Inc. has completed a Phase 1 study called “A Phase 1 Non-Randomized, Open-Label, Single Dose Study

Aligos Therapeutics, Inc. ($ALGS) announced an update on their ongoing clinical study. Aligos Hepatitis B Study Shows Progress in Liver-Impaired Patients. This Phase 1 study, titled “A Phase 1 Non-Randomized,

Reports Q2 revenue $27.78M, consensus $13.18M. “Our team has continued to execute on our key strategic priorities to advance our pipeline this year,” stated Lawrence Blatt, Chairman, President, and Chief

Aligos Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock and has a

Aligos Therapeutics (ALGS) announced that it has completed enrollment of both the HBeAg+ and HBeAg- participants in the Phase 2 B-SUPREME study of pevifoscorvir sodium, under development for the treatment

Risk-on sentiment resurfaced following the long holiday weekend as large-cap growth areas of the market handily outperformed SMIDs and value. Comms Services, Tech, and Financials were the best performing sectors

Aligos Therapeutics (ALGS) announced that it has received the upfront payment of $25M from the exclusive license deal of pevifoscorvir sodium in Greater China with Xiamen Amoytop Biotech. In addition,

Aligos Therapeutics ( ($ALGS) ) has provided an announcement. On June 25, 2026, Aligos Therapeutics, Inc. held its Annual Meeting of Stockholders, at which investors elected two Class III directors,
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 11, 2027TBA | $9.16M | $-2.03 | $614.00K | 0.04 | -0.20 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.